InvestSMART

Syntara Limited (ASX:SNT)

ALERT: Price-sensitive ASX Announcement for SNT
Current share price for SNT : $0.020 -0.002 (-9.09%)+
Announcement
Release
1 Oct 2026 9:49AM
Price at Release
$0.022
Full Release
download
Summary
Syntara Limited (ASX: SNT) announced that it is expanding the Phase 1b study of its second-generation topical pan-lysyl oxidase inhibitor, SNT-9465, in hypertrophic sternotomy scars from 20 to 30 participants while keeping the trial double-blind and placebo-controlled, with the expansion intended to strengthen the safety, tolerability and exploratory activity dataset rather than reflect any unblinded efficacy signal. The company said recruitment of the initial cohort is nearing completion, the protocol has been refined to improve application consistency, The Skin Hospital in Sydney has been added as an additional clinical site, and top-line results are now expected in Q1 2027. The release also updated the exploratory investigator-initiated SATELLITE study of first-generation topical pan-LOX inhibitor SNT-6302 in keloid scars, noting that six participants completed 12 weeks of treatment with preliminary biological findings, including increased blood-vessel area density, directionally consistent with observations from SOLARIA2, but no observable Week 12 differences in POSAS scores or scar stiffness; several participants experienced mild reversible local skin reactions and eight discontinued treatment, which Syntara said further supports advancement of the better-tolerated second-generation candidate SNT-9465.
Key Points
  • Syntara is expanding the SNT-9465 Phase 1b hypertrophic sternotomy scar study from 20 to 30 participants.
  • The study remains double-blind and placebo-controlled, and the expansion is intended to provide a larger and more robust safety, tolerability and exploratory activity dataset.
  • Recruitment of the initial 20-participant cohort is nearing completion.
  • The Skin Hospital in Sydney has been added as an additional clinical site to support recruitment.
  • Top-line results for the SNT-9465 study are expected in Q1 2027.
  • SNT-9465 is Syntara’s second-generation topical pan-LOX inhibitor designed to improve tolerability while retaining pan-LOX pharmacology.
  • In the exploratory SATELLITE keloid scar study of SNT-6302, six participants completed the 12-week treatment period and remain in follow-up.
  • Preliminary SNT-6302 findings showed increased blood-vessel area density at Week 12, directionally consistent with SOLARIA2 observations.
  • No observable Week 12 differences were identified in POSAS scores or scar stiffness in the SNT-6302 study.
  • Several participants experienced mild reversible local skin reactions, and eight discontinued treatment due to these reactions.
  • Syntara said the SNT-6302 tolerability profile supports the rationale for progressing SNT-9465.
  • Further end-of-treatment and follow-up data from the keloid scar study are still outstanding and may inform a future follow-on study.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.